Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2004-3-30
pubmed:abstractText
Introduction of specific cyclooxygenase (COX)-2 inhibitors holds the promise of improved treatment for inflammatory processes without the gastrointestinal effects associated with the conventional non-selective nonsteroidal anti-inflammatory drugs (NS-NSAID), which inhibit both COX-1 and COX-2 activity. Dysmenorrhea is a common inflammatory process that affects many adolescent girls, and is the leading cause of recurrent short-term school or work absenteeism among female adolescents and young adults. In vitro studies have shown that the selective COX-2 inhibitors have a potent tocolytic effect. In vivo studies have found the specific COX-2 inhibitors rofecoxib (Vioxx) and valdecoxib (Bextra) effective in treatment of primary dysmenorrhea in women >or=18 years. Adolescents suffering from dysmenorrhea with a prior history of peptic ulcer, or with a history of NS-NSAID gastrointestinal adverse effects, or who require high doses of NS-NSAID during the menstrual period, as well as adolescents with coagulation deficiencies, may benefit from the use of a specific COX-2 inhibitor. Studies are warranted to explore whether the specific COX-2 inhibitors are effective in treating dysmenorrhea in the adolescent age group.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1083-3188
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
75-9
pubmed:dateRevised
2005-11-17
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea.
pubmed:affiliation
Hasbro Children's Hospital, and Department of Pediatrics, Brown University, Providence, Rhode Island 02903, USA. ZHarel@Lifespan.org
pubmed:publicationType
Journal Article, Review